Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06605079
Recruiting Not applicable

Enhancing Palliative Care in ICU

NCT06605079 · tracked via the Priya Life Science Italy tracker
Sponsor
Charite University, Berlin, Germany
Phase
Not applicable
Started
2024-10-10
Last updated
2025-09-30

Condition(s) studied

Palliative Care

Investigational drug(s) / intervention(s)

Complex interventionRoutine treatment

Complex intervention: A complex intervention is carried out in the intensive care unit. This includes: * telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff * the training of hospital staff in the intensive care unit in basic palliative care and * the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs. The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed.

Routine treatment: No complex intervention is established, just routine procedures.

Study summary

The aim of this study is to reduce the suffering in intensive care through palliative care consultations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Patients: Inclusion Criteria: * Patients in ICU who can give consent and those who can not (via their authorized representative or legal guardian, also possible with delayed consent) * From 18 years * The leading cause of critical illness is not cancer * New admission on the participating ICU \> 72h * Assessment of the need for palliative care by the in-charge physi-cian of the ICU, because (1) there is a significant disagreement about ICU treatment or (2) because the physician considers ther-apy limitations for the patient or (3) the physician considers a benefit from specialized PC consultation for ICU physician, nurse, or patient or family. Exclusion Criteria: \- Patient is moribund and is expected to die within the next 24h Study cohort relatives: Inclusion criteria: \- At least one relative(s) of a patient. This may or may not be the legal representative, depending on national legislation. Exclusion criteria: * Refusal by the relative * Refusal of the patient to participate in the intervention study * \<18 years of age Cohort of employees: Inclusion criteria * Employed on the ITS as a doctor/nurse * Employed in the clinical center as a member of the palliative care consultation service Exclusion criterion Refusal to participate

Primary outcome measure(s)

  • Length of intensive care stay — During intensive care unit stay, an average of 5 days
    The primary endpoint is the number of days the patient spent in each Intensive Care Unit (ICU) of the index hospital during the first hospitalization. For example, if the patient was transferred from the first ICU participating in the EPIC study to another, second ICU within the same hospital, or if the patient was transferred back from a ward to the first ICU, the duration of the secondary ICU is included in the calculation of the primary endpoint.

Trial sites (31)

FacilityCityRegionStatus
ICU General Resuscitation (RES UP), General University hospital Prague Czechia Recruiting
ICU General Resuscitation (RES2) Prague Czechia Recruiting
ICU Metabolic, General University hospital Prague Czechia Recruiting
Department of Anesthesiology and Intensive Care Medicine (CCM/CVK),Charité - University Medicine Berlin Mitte State of Berlin Recruiting
Department of Anesthesiology and Intensive Care Medicine (CCM/CVK),Charité - University Medicine Berlin Wedding State of Berlin Recruiting
CARITAS Klinik Maria Heimsuchung Berlin Germany Recruiting
Charité - Department of Anesthesiology and Intensive Care Medicine CBF Berlin Germany Recruiting
Department of Cardiology, Angiology and Intensive Care Medicine | CVK, Charité - University Berlin Berlin Germany Recruiting
Evangelisches Krankenhaus Hubertus Berlin Germany Recruiting
Unfallkrankenhaus Berlin Berlin Germany Withdrawn
Medical and Neurological Intensive Care Unit, University Hospital of Düsseldorf Düsseldorf Germany Recruiting
Neurosurgical and Traumatological ICU ZI13, University Hospital of Düsseldorf Düsseldorf Germany Recruiting
Surgical Intensive Care Unit CIA1/CIB1, University Hospital of Düsseldorf Düsseldorf Germany Recruiting
Universitätsklinikum Halle (Saale): Klinik für Innere Medizin III Halle Germany Recruiting
Johanna-Etienne Hospital Neuss, Interdisciplinary ICU Neuss Germany Recruiting
Ev. Krankenhaus Paul-Gerhardt-Stift Wittenberg:Angiologie und Kardiologie Wittenberg Germany Withdrawn
Department of Intensive Care Medicine, University Hospital of Heraklion Heraklion Crete Recruiting
Department of Intensive Care Medicine, University Hospital of Patras Pátrai Rio Recruiting
Department of Intensive Care Medicine, University Hospital of Alexandroupolis Alexandroupoli Greece Recruiting
Cardiothoracic Intensive Care Unit of the Onassis Cardiac Surgery Center Athens Greece Recruiting
Department of Intensive Care Medicine, Alexandra General Hospital Athens Greece Recruiting
Department of Intensive Care Medicine, Evaggelismos General Hospital Athens Greece Recruiting
Department of Intensive Care Medicine, University Hospital of Ioannina Ioannina Greece Recruiting
University Hospital of Larissa, Critical Care Department Larissa Greece Recruiting
General Intensive Care Unit, Hadassah Medical Organisation Jerusalem Israel Recruiting
The Coronary Care Intensive Care Unit, Hadassah Hospital, Ein Kerem Jerusalem Israel Recruiting
The Neurosurgical Intensive Care Unit, Hadassah Hospital, Ein Kerem Jerusalem Israel Recruiting
S.C. Anestesia e Rianimazione 1 - Terapia Intensiva Cardiochirurgica, Azienda Ospedaliera Universitaria S. Maria della Misericordia Perugia Italy Withdrawn
S.C. Anestesia e Rianimazione 2 - Terapia Intensiva, Azienda Ospedaliera Universitaria S. Maria della Misericordia Perugia Italy Recruiting
UOC di Anestesia e Rianimazione Cardio Toraco Vascolare dell'AOU San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Salerno University Hospital Salerno Italy Recruiting
S.C. Anestesia - Rianimazione Azienda Ospedaliera Santa Maria - Terni Terni Italy Withdrawn

More Charite University, Berlin, Germany trials in Italy

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Starting soon
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Recruiting

Other trials for the same condition

Evaluation of Toxicities in Patients Treated With Palliative Radiotherapy at Policlinico Sant Orsola of Bologna. Recruiting
MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care Recruiting
Complex Decisions Regarding Antithrombotic Therapy: the QUIET Study Starting soon
Antithrombotic Therapy at the End of Life: The PEACE Study Starting soon
Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06605079 on ClinicalTrials.gov ↗ ← All trials in Italy